0      0

AONN+ Annual 2020

SAT05 - Product Theater 7 | Insights on Managing Patients with CLL and MCL on a Selective BTK Inhibitor Therapy (non-CE) Presentation by AstraZeneca


Nov 7, 2020 10:00am ‐ Nov 7, 2020 11:00am


Description

The “Insights on Managing Patients with CLL and MCL on a Selective BTK Inhibitor Therapy” deck presents a general overview of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) epidemiology and disease pathogenesis along with a review of the efficacy and safety profile of a selective BTK inhibitor. To empower patients and care teams to effectively manage patients on treatment with a selective BTK inhibitor and encourage adherence, detailed information on best practices for adverse event management.

HCP Website

CLL Dosing Guide

Request A Representative

Speaker(s):

You must be logged in and own this session in order to post comments.